ÌÇÐÄvlog

This population-based study examines the incidence and risks for development of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) in patients who have received chemotherapy for primary solid cancers.

This national survey study of patients with cancer evaluates the association between patient comorbid conditions and cancer clinical trial participation.

This phase 1b multicohort study assessed 33 patients with advanced triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel to examine its safety, tolerability, and preliminary clinical activity.

This multicenter, phase 2, single-arm trial assesses the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type metastatic colorectal cancer who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy.

This phase 1b clinical trial assesses the safety and efficacy of avelumab treatment in a multinational cohort of patients with unresectable, previously treated malignant mesothelioma.

This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.

This study examines HER2 ISH-equivocal breast cancers to asses 2013/2014 American Society of Clinical Oncology and College of American Pathologists guidelines in determining HER2-positive or HER2-negative breast cancers and false-positive results.

This medical records analysis from a single institution in Japan assesses anti–PD-1 treatment in patients with subclinical advanced non–small cell lung cancer and with or without preexisting autoimmune markers and evaluates potential clinical biomarkers that may be associated with clinical benefit or with immune-related adverse events.

This cross-sectional study analyzes the proportion of cancer cases attributable to excess body weight in each US state using data from several databases.

This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.

This secondary analysis of a randomized clinical trial examines the association of modern chemoradiotherapy with survival among patients with stage I to II small cell lung cancer compared with that among patients with stage III small cell lung cancer.